Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Sri Harsha TellaNathan FosterQian ShiTran NguyenMitesh J BoradRobert R McWilliamsSteven R AlbertsWen Wee MaSakti ChakrabartiBriant FruthJaclynn WesslingMindy HartgersLeslie WashburnMartin E Fernandez-ZapicoTara L HogensonHenry PitotZhaohui JinAmit MahipalPublished in: The oncologist (2023)
The combination of trifluridine/tipiracil plus irinotecan is a potential treatment option for patients with advanced, refractory BTCs with good functional status and no targetable mutations. A larger randomized trial is needed to confirm these results. (ClinicalTrials.gov Identifier: NCT04072445).